HAYWARD, Calif., March 31 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated today announced that Robert G. Johnson, Jr., M.D., Ph.D., Chief Executive Officer, will present at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference in New York at the Millennium Broadway Hotel on Tuesday, April 4, 2006 at 11:30 a.m. Eastern Time.
Interested parties may access a live webcast of Dr. Johnson’s presentation by visiting the Calendar of Events page under News and Events on Kosan’s website at http://www.kosan.com .
It is recommended that listeners log on 15 minutes early in order to register and download any necessary software. If you are unable to participate during the live webcast, a recorded replay of the presentation will be available one hour after the presentation is completed for two weeks.
About Kosan
Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development. Its heat shock protein 90, or Hsp90, inhibitor, KOS-953, is in Phase I and II clinical trials, primarily for multiple myeloma and HER2 positive breast cancer. KOS-953 is Kosan’s proprietary formulation of 17-AAG, a geldanamycin analog. In addition, intravenous and oral formulations of its second-generation Hsp90 inhibitor, KOS-1022, are currently in Phase I clinical trials. These compounds have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival.
Kosan is also developing KOS-862 in Phase II clinical trials in breast cancer. KOS-862 is an epothilone with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. Its follow-on epothilone, KOS-1584, is in Phase I clinical trials. Its epothilone program is partnered with Hoffmann-La Roche, Inc. and F. Hoffmann-La Roche Ltd., collectively Roche, through a global development and commercialization agreement. For additional information about Kosan Biosciences, please visit the company’s website at www.kosan.com.
Kosan Biosciences Incorporated
CONTACT: Robert G. Johnson, Jr., M.D., Ph.D, Chief Executive Officer ofKosan Biosciences Incorporated, +1-510-732-8400, ext. 5243, orjohnson@kosan.com
Web site: http://www.kosan.com/
